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Over 20% of patients with cirrhosis are nonadherent with hepatocellular carcinoma (HCC) surveillance recommendations;
however, few studies have evaluated the impact of patient-level factors on surveillance receipt. We characterized the associ-
ation between HCC surveillance receipt and patient knowledge, attitudes, and perceived barriers in a racially diverse and
socioeconomically disadvantaged cohort of patients with cirrhosis. Patients with cirrhosis followed at a large urban hospital
were invited to complete a survey about HCC surveillance between August 2014 and December 2015. Multivariable logis-
tic regression was performed to identify factors associated with HCC surveillance receipt during the 12-month period pre-
ceding and 6-month period after survey administration. We achieved a response rate of 71.8% (n 5 541 of 753). Patients
demonstrated high levels of HCC-related knowledge (summary score, 77.7%); however, 48.6% believed that eating a
healthy diet precluded the need for HCC surveillance, and 34.0% believed that HCC surveillance was not necessary if
they had a normal physical exam and/or lacked clinical symptoms. Patients expressed worry about developing and dying
from HCC, but nearly half (49.9%) of patients reported barriers to receiving HCC surveillance, including difficulty with
the scheduling process (30.5%), costs of surveillance testing (25.3%), and transportation difficulties (17.3%). HCC surveil-
lance receipt was significantly higher in patients who knew cirrhosis is a risk factor for developing HCC (odds ratio [OR],
3.09; 95% confidence interval [CI], 1.25-7.62) and significantly lower in those reporting barriers to surveillance (OR, 0.42;
95% CI, 0.25-0.70). Conclusion: Patients with cirrhosis are knowledgeable and interested in HCC surveillance; however,
patient-reported barriers are associated with lower surveillance rates in clinical practice and represent potential intervention
targets to improve HCC surveillance effectiveness. (HEPATOLOGY 2017;65:875-884).
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Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death world-wide and one of the leading causes of death
in patients with cirrhosis.(1) Prognosis for patients with
HCC depends on tumor stage at diagnosis, with cura-
tive options only available for patients diagnosed at an
early stage.(2) Despite improvement in overall survival
over time, most patients continue to be diagnosed at
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socioeconomic status.
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advanced stages and 5-year survival rates remain below
20%.(3) Racial/ethnic minorities have higher rates of
late-stage tumor detection as well as significantly lower
stage-adjusted survival rates than non-Hispanic
Caucasians.(4,5)
Poor HCC clinical outcomes are, in part, attributed
to underuse of surveillance among at-risk patients with
cirrhosis. Several cohort studies have demonstrated
that HCC surveillance is associated with higher rates
of early tumor detection, curative treatment receipt,
and overall survival(6); however, fewer than 20% of
patients with cirrhosis in the United States undergo
HCC surveillance.(7) HCC surveillance rates are even
lower among racial-ethnic minorities and patients of
low socioeconomic status (SES), likely related to a
combination of medical, socioeconomic, and cultural
issues.(8)
Although provider recommendation is reported to
be a strong predictor for HCC surveillance,(9) patient-
level factors may also play an important role in surveil-
lance underuse. In prospective cohort studies, nearly 1
in 5 patients were nonadherent with provider recom-
mendations for HCC surveillance.(10,11) The cancer-
screening literature has applied theoretical models of
behavior change and demonstrated that patients’ poor
knowledge, negative attitudes, or perceived barriers to
cancer screening may be associated with lower screen-
ing rates.(12,13) However, most studies evaluating
HCC surveillance correlates have primarily focused on
patient sociodemographic and clinical characteris-
tics.(7,14) The effect of theory-based, patient-reported
psychosocial factors on HCC surveillance completion
has not been quantified. A better understanding of
patient knowledge, attitudes, and barriers, particularly
among low-income minorities, is crucial to develop
and implement effective interventions to improve
HCC surveillance rates.(15) Therefore, the aim of our
study was to characterize patient-level knowledge, atti-
tudes, and barriers regarding HCC surveillance and
their association with receipt of HCC surveillance in a
racially diverse and socioeconomically disadvantaged
cohort of patients with cirrhosis.
Patients and Methods
STUDY POPULATION
Electronic medical records of patients being
observed at Parkland Health and Hospital System
(Parkland), the safety net health system of Dallas
County, were screened to identify adult patients with
cirrhosis. Parkland is an integrated health care system
including 12 primary care provider clinics, outpatient
hepatology and multidisciplinary liver tumor clinics,
and a tertiary hospital—all sharing a single electronic
medical record (EMR) system.
Patients were initially identified using a validated set
of International Classification of Diseases, Ninth Revi-
sion codes for cirrhosis (571.2, 571.5) or cirrhosis com-
plications (456.0, 456.1, 456.2, 456.21, 567.23, 572.2,
572.3, and 572.4).(16) Presence of cirrhosis was then
confirmed by chart review before survey administration
by one of the authors (A.S., M.K., or J.P.), with diagno-
sis based on consistent histology, noninvasive markers
of fibrosis, including FibroSure, or imaging showing a
cirrhotic-appearing liver with associated signs of portal
hypertension, including splenomegaly, varices, or
thrombocytopenia. We excluded patients with (1) grade
3-4 encephalopathy, (2) patient self-reported low litera-
cy precluding survey completion, (3) language other
than English or Spanish, (4) personal history of HCC,
or (5) history of liver transplantation (LT). The study
was approved by the Institutional Review Board of UT
Southwestern Medical Center (Dallas, TX).
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SURVEY DEVELOPMENT AND
ADMINISTRATION
Eligible patients were recruited to complete the sur-
vey at the time of a clinic appointment or by telephone
between August 2014 and December 2015. A conve-
nience sample of patients were approached in the wait-
ing room by one of the study investigators (S.F. or
J.P.) before their clinic appointment, consented, and
asked to complete a self-administered paper survey.
Study investigators (S.F or M.K) also consented and
administered the survey by telephone to a random
sample of patients with cirrhosis who did not have an
upcoming clinic appointment.
We used a theoretical model of patient behavior for
HCC surveillance (Fig. 1), based on the Health
Behavior Framework, to guide selection of relevant
variables for survey development.(17,18) The survey
took approximately 20 minutes to complete and was
divided into four sections: (1) knowledge about HCC,
(2) potential barriers to HCC surveillance completion,
(3) patient attitudes, and (4) demographic information.
The first section assessed level of knowledge and con-
sisted of 12 true-false questions with three domains:
five questions regarding HCC risk and need for sur-
veillance, four questions about surveillance logistics
and effectiveness, and three questions about HCC
treatment and prognosis. The second section assessed
the presence of potential patient-, provider-, and
system-level barriers to HCC surveillance completion,
including patient refusal, financial or transportation
concerns, lack of provider recommendation, and
scheduling difficulties using yes/no response options.
The section assessing patient attitudes included two
domains: worry about HCC and information-seeking
behavior. The patient apprehension domain estimated
patient level of concern about developing HCC and/or
dying from HCC as well as any impact of surveillance
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FIG. 1. Model of patient behavior for
HCC surveillance.
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on level of concern using a 5-point Likert scale.
Information-seeking questions assessed confidence in
current level of HCC-related knowledge and desire for
more information. Demographic information included
age, sex, race and ethnicity, marital status, living situa-
tion, level of education, employment status, and house-
hold income. Questions were adapted from earlier
validated surveys when available.(19,20) After initial
development of the survey, we pretested it using cogni-
tive interviewing methods with 10 English-speaking
and 10 Spanish-speaking patients.(21,22)
EMR DATA COLLECTION
Additional correlates, including patient demographics,
clinical history, and laboratory data, were obtained
through standardized abstraction of the EMR. We did
not collect provider- or clinic-level characteristics,
although we previously demonstrated that there are no
differences in clinic practices supporting HCC surveil-
lance.(19) Patient age, sex, race, ethnicity, preferred lan-
guage, and insurance type as reported on the survey were
verified using EMR data. We detailed drug, alcohol,
and smoking history, with active alcohol abuse defined
as drinking more than 40 g/day. Patients were classified
according to etiology of liver disease using laboratory
data and clinical notes as follows: hepatitis C virus
(HCV; positive HCV antibody or viral load); hepatitis B
virus (positive hepatitis B surface antigen or viral load),
alcohol-related liver disease (as determined by clinic pro-
vider), nonalcoholic steatohepatitis (NASH; presence of
metabolic syndrome in absence of other causes of chron-
ic liver disease or as determined by clinic provider), and
other. Data regarding presence of decompensation (asci-
tes or hepatic encephalopathy [HE]) were abstracted
from clinical notes and classified as none, mild or con-
trolled, and severe or uncontrolled. Laboratory data of
interest at time of survey administration included platelet
count, creatinine, bilirubin, albumin, and international
normalized ratio.
STUDY OUTCOMES
Our primary outcome of interest was receipt of abdom-
inal imaging for surveillance purposes within the 12-
month period preceding and 6-month period after survey
administration. We evaluated surveillance completion
instead of patients’ intent to complete surveillance because
it could be collected in a standardized and objective man-
ner using EMR data. We only included imaging for sur-
veillance purposes because patient knowledge and
attitudes about HCC surveillance would not affect the
likelihood of having exams for diagnostic purposes. We
used a study period surrounding the time of survey
administration to minimize potential for changes in
patient knowledge or attitudes. We recorded all imaging
(ultrasound, contrast-enhanced computed tomography, or
contrast-enhanced magnetic resonance imaging) and
alpha fetoprotein (AFP) results during the study period.
Imaging performed at outside institutions were included
if results were recorded in the EMR. Intent of imaging
(surveillance vs. nonsurveillance purposes) was determined
through review of imaging orders and associated clinical
notes. Indications, including “surveillance,” “screening,”
“rule out HCC,” and “cirrhosis” were classified as surveil-
lance indications, whereas exams performed for any symp-
toms or signs, for example, abdominal pain or elevated
liver enzymes, were classified as diagnostic exams.
Surveillance receipt was first characterized as an
ordinal outcome: consistent surveillance (1 imaging
study during each 6-month period); inconsistent sur-
veillance (1 imaging study during each study period,
but not meeting criteria for semiannual surveillance);
and no surveillance. Given the small number of
patients with consistent surveillance, patients with
consistent and inconsistent surveillance were combined
for correlates analyses.
A secondary outcome of interest was overall patient
knowledge. Each of the 12 true-false questions in the
survey was awarded 1 point if correct and 0 if incorrect,
“don’t know,” or left blank. A summary scale of the
items was created, with higher scores indicating more
accurate knowledge.
STATISTICAL ANALYSIS
Distributions of patient characteristics and percep-
tions of surveillance were reported with descriptive sta-
tistics. Univariate and multivariable logistic regression
was performed to identify factors (patient knowledge,
attitudes, barriers, and EMR-derived clinical variables)
associated with our dichotomous measure of HCC
surveillance receipt (any surveillance vs. no surveil-
lance). The multivariable model included variables of a
priori clinical importance (e.g., race/ethnicity, Child
Pugh score) and factors significant on univariate analy-
ses. Predictor variables with P < 0.10 in univariate
analyses were included in multivariable models to min-
imize type 2 error. Statistical significance was defined
as P < 0.05 for multivariable analyses. We required
480 patients to have 90% power to detect a difference
of 15% in HCC surveillance rates,(18) assuming a
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baseline surveillance rate of 50% and prespecified alpha
of 0.05. To identify factors associated with overall
patient knowledge, we performed a secondary analysis
using multivariable ordinal logistic regression. The
multivariable model included variables of a priori clini-
cal importance (e.g., race/ethnicity, educational attain-
ment) and factors significant on univariate analyses.
All data analysis was performed using Stata software
(version 11; StataCorp LP, College Station, TX).
Results
PATIENT CHARACTERISTICS
Of 753 patients approached, 541 (71.8%) agreed to
complete the survey, including 384 patients who
completed the survey in clinic and 157 by telephone.
Reasons for nonresponse include nonworking phone
number or did not answer telephone (n 5 109),
patient refusal (n 5 52 by telephone and 32 in clinic),
and being admitted to the hospital, rehab facility, or
jail (n 5 19). Patient characteristics are detailed in
Table 1. Median age was 56 years (interquartile range
[IQR], 51-61) and 56.4% were male. The cohort was
racially/ethnically diverse, with 43.4% Hispanics,
27.4% non-Hispanic Caucasians, and 25.7% blacks.
Most (73.0%) patients had Medicaid or were covered
by a county medical assistance plan, 23.3% had Medi-
care, and 3.7% had private insurance. The most com-
mon etiologies of cirrhosis were HCV infection
(50.7%), alcohol-induced (26.0%), and NASH/crypto-
genic (10.2%). Most patients had compensated cirrho-
sis, with 48.7% having Child Pugh A cirrhosis, 36.5%
Child Pugh B cirrhosis, and 14.8% Child Pugh C cir-
rhosis. Ascites was present in 48.2% of patients, and
30.5% had grade I-II HE.
TABLE 1. Patient Characteristics
Characteristic
Receipt of Any
Surveillance
(n 5 356)
No
Surveillance
(n 5 185)
Age, years 55.4 6 8.6 55.1 6 10.1
Sex, % male 206 (57.9) 99 (53.5)
Race/ethnicity (%)
Non-Hispanic Caucasian 100 (28.1) 48 (25.9)
Black 84 (23.6) 55 (29.7)
Hispanic 157 (44.1) 78 (42.2)
Other/unknown 15 (4.2) 4 (2.2)
Primary language, % English 273 (76.7) 144 (77.8)
Insurance status (%)
Uninsured 160 (44.9) 94 (50.8)
Medicaid 102 (28.7) 39 (21.1)
Medicare 80 (22.5) 46 (24.9)
Private insurance 14 (3.9) 6 (3.2)
Educational attainment (%)
Did not graduate high school 92 (25.8) 38 (20.5)
High school degree 168 (47.2) 86 (46.5)
Attended but did not
graduate college
74 (20.8) 51 (27.6)
College degree 20 (5.6) 10 (5.4)
Annual household income (%)
Less than $10,000 233 (65.4) 126 (68.1)
$10,000-$20,000 70 (19.7) 31 (16.8)
Greater than $20,000 38 (10.7) 21 (11.4)
Not reported 15 (4.2) 7 (3.8)
Marital status, % married 112 (31.5) 53 (28.7)
Living situation, % alone 80 (22.5) 46 (24.9)
Etiology of liver disease (%)
Hepatitis C 190 (53.4) 83 (44.9)
Hepatitis B 8 (2.2) 6 (3.2)
Alcohol-related 91 (25.6) 49 (26.5)
NASH 34 (9.5) 21 (11.4)
Other 33 (9.3) 26 (14.0)
Child Pugh class (%)
A 166 (48.4) 74 (49.3)
B 122 (35.6) 58 (38.7)
C 55 (16.0) 18 (12.0)
Presence of HE (%) 120 (33.7) 45 (24.3)
Presence of ascites (%) 175 (49.2) 86 (46.5)
Receipt of hepatology care (%) 327 (91.9) 135 (73.0)
TABLE 2. Proportion of Patient Knowledge Items Answered
Correctly
Knowledge Item
Proportion Correct
(n 5 541)
Patients with cirrhosis are at high risk for
developing HCC (%)
491 (90.8)
Eating a healthy diet does not sufficiently
lower HCC risk to preclude a need
for surveillance (%)
278 (51.4)
Lack of abdominal pain does not preclude
need for HCC surveillance (%)
433 (80.0)
Patients with two consecutive normal
surveillance ultrasound exams require
continued HCC surveillance (%)
387 (71.5)
Normal physical exam and labs does not
preclude need for HCC surveillance (%)
357 (66.0)
Ultrasound is the primary recommended
modality for HCC surveillance (%)
462 (85.4)
Patients with cirrhosis should have HCC
surveillance performed at least once
per year (%)
478 (88.4)
Surveillance does not prevent
development of HCC (%)
418 (77.3)
Surveillance does not preclude
diagnosis with advanced HCC (%)
392 (72.5)
HCC can be cured if diagnosed at an
early stage (%)
429 (79.3)
Patients with HCC will die without
cancer treatment (%)
419 (77.5)
HCC does not spontaneously resolve
without cancer treatment (%)
501 (92.6)
Summary score for all questions, % (n 5 12) 77.7
Summary score for risk factors
questions, % (n 5 5)
71.9
Summary score for surveillance logistics
and efficacy questions, % (n 5 4)
80.9
Summary score for treatment questions, % (n 5 3) 83.1
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PATIENT KNOWLEDGE OF HCC
SURVEILLANCE
The percent of correct responses for each of the 12
knowledge questions ranged from 51.4% to 92.6%
(Table 2). Patients demonstrated lower levels of
knowledge about HCC risk factors than HCC surveil-
lance and treatment logistics and effectiveness (P <
0.001). Although over 90% of patients knew that
patients with cirrhosis are higher risk for HCC than
those without cirrhosis, there were several notable
knowledge deficiencies. Nearly half believed eating a
healthy diet could sufficiently lower risk of HCC to no
longer require HCC surveillance. Similarly, 20% of
patients erroneously believed HCC surveillance is not
necessary in the absence of abdominal pain, 28.5%
believed HCC surveillance can be stopped after a cou-
ple normal ultrasound exams, and 34% believed HCC
surveillance is not necessary if their physical exam is
normal.
Factors associated with higher levels of overall
knowledge on univariate analysis (Table 3) included
Caucasian race, English as primary language, HCV-
related cirrhosis, Child Pugh A cirrhosis, receipt of
hepatology subspecialty care, higher educational attain-
ment, and high perceived likelihood of dying from
HCC. Being married, living alone, and lack of insur-
ance were associated with lower levels of knowledge.
Because of collinearity between language and race/eth-
nicity, language was not included in the multivariable
model. Age, sex, and self-reported household income
were examined, but were not significant on univariate
analysis. On multivariable analysis, increased level of
knowledge was significantly associated with Caucasian
race, Medicare insurance status, receipt of hepatology
subspecialty care, and higher educational attainment
(Table 3).
PATIENT ATTITUDES ABOUT
HCC SURVEILLANCE
Patients demonstrated high levels of worry regarding
HCC (42.3% worried and 24.0% extremely worried),
with 282 (52.1%) expressing concern that they are like-
ly to develop HCC in their lifetime and 250 (46.3%)
expressing concern they are likely to die from HCC.
Only 40 (7.4%) patients believed they are extremely
unlikely to die from HCC. Patients expressed reassur-
ance from undergoing HCC surveillance, with 375
(69.4%) reporting HCC surveillance is likely to find
HCC at an early stage allowing curative therapy and
221 (41.0%) reported HCC surveillance decreases their
risk of dying from HCC. Accordingly, 89.5% of
patients rated having knowledge about HCC
TABLE 3. Predictors of Higher Patient Knowledge
Variable
Univariate Models
OR (95% CI)
Multivariable Model
AOR (95% CI)*
Race/ethnicity
Non-Hispanic
Caucasian
Reference Reference
Black 0.46 (0.30-0.70) 0.53 (0.33-0.85)
Hispanic 0.20 (0.14-0.30) 0.38 (0.24-0.61)
Other/unknown 0.37 (0.15-0.91) 0.53 (0.21-1.31)
English language as
preferred language
3.83 (2.67-5.48) Collinear
Insurance status
Uninsured Reference Reference
Medicaid 1.49 (1.04-2.15) 1.25 (0.84-1.87)
Medicare 1.73 (1.18-2.53) 1.75 (1.15-2.65)
Private insurance 0.96 (0.45-2.04) 1.0 (0.42-2.38)
Educational attainment
Did not graduate
high school
Reference Reference
High school degree 3.03 (2.07-4.43) 2.14 (1.41-3.26)
Attended but did not
graduate college
3.84 (2.46-6.00) 2.68 (1.61-4.44)
College degree 5.79 (2.77-12.11) 3.20 (1.42-7.20)
Marital status
(being married)
0.55 (0.40-0.76) NS
Living alone 1.43 (1.01-2.03) NS
HCV etiology of cirrhosis 1.79 (1.33-2.42) NS
Child Pugh A cirrhosis 1.42 (1.03-1.94) NS
Perceived likelihood of
dying from HCC
1.57 (1.16-2.12) NS
Receipt of hepatology care 1.49 (1.10-2.00) 1.45 (1.05-2.01)
*Significant associations in bold.
Abbreviations: AOR, adjusted odds ratio; NS, not significant.
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FIG. 2. Patient-reported barriers to HCC surveillance.
                                                                 
FARVARDIN, PATEL, ET AL. HEPATOLOGY, March 2017
880
surveillance as important, and 88.8% believed it is
important to undergo HCC surveillance.
PATIENT-REPORTED BARRIERS
TO HCC SURVEILLANCE
The prevalence of patient-reported barriers to HCC
surveillance is illustrated in Fig. 2. The most common
perceived barriers to HCC surveillance were difficulty
with the scheduling process for ultrasound exams
(30.5%), costs of surveillance tests (25.3%), uncertainty
of where to get surveillance ultrasound performed
(19.6%), and difficulty with transportation (17.3%).
Half (49.9%) of patients reported at least one of these
barriers, with 22.8% reporting a multitude of these
barriers. Perceived poor surveillance test efficacy
(13.9%), fear of finding cancer (11.3%), time commit-
ment (10.2%), and fear of pain from surveillance tests
(9.5%) were uncommon barriers to HCC surveillance.
HCC SURVEILLANCE RECEIPT
Surveillance imaging was performed at least once
during the study period in 356 (65.8%) patients, with
only 15 (2.8%) having consistent surveillance every 6
months. An additional 91 patients received ultrasound
imaging for nonsurveillance purposes and were classi-
fied as having no surveillance. AFP was performed at
least once during the study period in 92.4% of 356
patients with imaging-based surveillance and 70.2% of
the 185 patients without imaging-based surveillance.
In univariate analysis, receipt of any surveillance was
directly associated with hepatology subspecialty care
(70.8% vs. 36.7%; P < 0.001), HCV etiology of cir-
rhosis (69.6% vs. 62.4%; P 5 0.08), reporting lower
levels of HCC-related worry because of surveillance
(69.3% vs. 60.9%; P 5 0.04), belief that HCC surveil-
lance reduces chance of dying from HCC (71.5% vs.
63.7%; P 5 0.10), and knowledge that cirrhosis is a
primary risk factor for HCC development (67.0% vs.
54.2%; P 5 0.08). Receipt of HCC surveillance was
inversely associated with the presence of patient-
reported barriers to surveillance (53.6% vs. 71.1%; P 5
0.001). Receipt of HCC surveillance was not associat-
ed with patient age (P 5 0.74), sex (P 5 0.33), Cauca-
sian race (P 5 0.60), or English as primary language
(P 5 0.76). Similarly, we did not find an association
between receipt of surveillance and overall level of
knowledge (P 5 0.89), perceived importance of under-
going surveillance (P 5 0.62), or perceived likelihood
of developing HCC (P 5 0.36).
In multivariable analysis, receipt of any surveillance
was positively associated with receipt of hepatology
subspecialty care (odds ratio [OR], 2.65; 95% confi-
dence interval [CI], 1.30-5.41), HCV etiology of cir-
rhosis (OR, 2.08; 95% CI, 1.19-3.63), and patient
knowledge that cirrhosis is a high-risk state for devel-
oping HCC (OR, 3.09; 95% CI, 1.25-7.62); presence
of any of the commonly reported barriers was inversely
associated with receipt of HCC surveillance (OR,
0.42; 95% CI, 0.25-0.70; Table 4).
In a post-hoc analysis, receipt of imaging for any
reason over the 18-month period was directly associat-
ed with receipt of hepatology care (OR, 4.77; 95% CI,
2.63-8.64) and inversely associated with the presence
of any of the commonly reported barriers to surveil-
lance (OR, 0.47; 95% CI, 0.30-0.74). We did not find
an association between receipt of any imaging and
patient age (P 5 0.64), sex (P 5 0.36), Caucasian race
(P 5 0.94), HCV etiology (P 5 0.75), overall level of
knowledge (P 5 0.58), or knowledge that cirrhosis is a
high-risk state for developing HCC (P 5 0.77).
TABLE 4. Predictors of HCC Surveillance Receipt
Variable
Univariate Models
OR (95% CI)
Multivariable Model*
AOR (95% CI)
Age (continuous) 1.00 (0.98-1.02) †
Female sex 0.84 (0.59-1.20) †
Caucasian race 1.11 (0.74-1.67) †
English as primary language 0.94 (0.61-1.43) †
HCV etiology of cirrhosis (vs. other etiologies) 1.37 (0.96-1.97) 2.09 (1.20-3.65)
Receipt of hepatology care 4.18 (2.53-6.88) 2.64 (1.30-5.40)
Knowledge: Cirrhosis is risk factor for HCC 1.72 (0.94-3.13) 3.02 (1.23-7.39)
Attitude: Surveillance reduces HCC mortality 1.43 (0.94-2.19) NS
Attitude: Surveillance reduces worry about HCC 1.45 (1.01-2.07) NS
Patient-reported barriers to HCC surveillance 0.47 (0.30-0.73) 0.42 (0.25-0.70)
*Adjusted for race/ethnicity and Child Pugh class A cirrhosis given a priori importance. Significant associations in bold.
†Not entered into multivariable model because of lack of significance in univariate analyses.
Abbreviations: AOR, adjusted odds ratio; NS, not significant.
HEPATOLOGY, Vol. 65, No. 3, 2017 FARVARDIN, PATEL, ET AL.
881
Discussion
To the best of our knowledge, our study is the first
survey assessing patient knowledge, attitudes, and bar-
riers for HCC surveillance in a racially diverse and
socioeconomically disadvantaged cohort of patients.
We found that patients demonstrated high levels of
HCC-related knowledge and expressed concern for
developing and dying from HCC; however, they
reported several barriers to receiving HCC surveillance,
including difficulty with the scheduling process, costs
of surveillance testing, and transportation difficulties.
Surveillance rates were significantly higher in patients
who knew cirrhosis was a risk factor for HCC develop-
ment and significantly lower in those who reported
barriers to HCC surveillance, suggesting that patient
knowledge deficits and surveillance barriers may be
important intervention targets to increase HCC sur-
veillance rates in the United States.
Although a past survey study from the University of
Michigan among 160 patients with cirrhosis reported
high levels of knowledge about HCC risk, surveillance
logistics, and treatment, this patient population repre-
sented a highly selected patient population (>80%
Caucasian, >63% college educated, and highly
insured) and may not be applicable to other popula-
tions.(20) Our current survey was administered in a
racially diverse and socioeconomically disadvantaged
cohort of patients followed in a large safety net health
system. Patient knowledge, attitudes, and barriers of
this population are particularly important to under-
stand given increased HCC risk, lower surveillance
rates, and worse prognosis among racial/ethnic minori-
ties and patients of low SES.(4,23,24)
Despite differences in patient populations, patients
demonstrated high levels of basic knowledge regarding
HCC risk, surveillance logistics, and prognosis. Most
important, 90% of patients understood that cirrhosis is
a high-risk state for HCC and that ultrasound-based
surveillance should be performed every 6-12 months.
However, HCC surveillance rates were significantly
lower among the subset of patients who did not know
that patients with cirrhosis were at high risk for devel-
oping HCC, highlighting the importance of discussing
this issue with all patients with cirrhosis. We also
found several other knowledge deficiencies that war-
rant targeted patient education efforts. Nearly half of
patients believed that eating a healthy diet could pre-
clude the need for HCC surveillance, and over one
third believed that HCC surveillance was not necessary
if they had a normal physical exam and/or were
asymptomatic. Furthermore, over one fourth of
patients believed that HCC surveillance could be
stopped after two normal ultrasound exams, potentially
partly explaining “surveillance fatigue” and decreasing
adherence rates as patients are followed over time.
Overall, patients expressed high levels of concern for
developing and/or dying from HCC. Although they
expressed reassurance in terms of HCC surveillance
improving early tumor detection, less than half of
patients believed that HCC surveillance reduces mor-
tality. This uncertainty regarding HCC surveillance’s
survival benefit could contribute to patients placing a
lower priority on HCC surveillance and lead to nonad-
herence with surveillance recommendations. The rea-
son for the disparity in reassurance for early tumor
detection and mortality reduction is unclear, but may
relate to how providers communicate benefits of HCC
surveillance. A similar pattern was noted in a survey
study among primary care providers caring for patients
with cirrhosis.(19) Provider communication style and
their level of enthusiasm for cancer screening benefits
has been a strong predictor of adherence in colon and
breast cancer screening.(25) If provider communication
also impacted HCC surveillance adherence, this would
highlight the need for higher-quality data characteriz-
ing the survival benefit of HCC surveillance in patients
with cirrhosis. These data would also support studies
evaluating the impact of interventions, such as provider
communication training or audit feedback, on patient
attitudes and surveillance adherence.(26)
Nearly half of all patients reported issues with ultra-
sound scheduling, costs, transportation, or uncertainty
where to get surveillance ultrasound performed.
Although these barriers are likely more common
among socioeconomically disadvantaged patients, they
highlight important intervention targets that can
increase HCC surveillance rates. Effective intervention
strategies can be adapted from breast and colon cancer
screening programs, where similar barriers have been
reported.(27-30) Simple reassurance about insurance
coverage may be sufficient to allay fears of surveillance
costs, and having clinic staff schedule ultrasounds the
same day as clinic visits can likely mitigate patient
issues with ultrasound scheduling, transportation, and
uncertainty regarding potential surveillance sites.
Comparative effectiveness trials evaluating intervention
strategies to address patient-reported barriers are
needed.
It is important to note that our study had limita-
tions. Our study was performed in a single large, safety
net hospital and may not be generalized to other
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practice settings. For example, our results might not be
generalizable to patients associated with transplant
centers given that most patients in safety net health
systems are not eligible for LT given social and/or
financial barriers.(31) However, we feel this study popu-
lation is particularly important to evaluate given higher
incidence and mortality rates among racial/ethnic
minorities and socioeconomically disadvantaged
patients. A national survey is needed to see whether
our data are representative of patients receiving care in
other settings. Survey studies are inherently limited by
response and recall biases. Although we had a high
response rate (>70%), there is also the possibility of
nonresponse bias, in which patients knowledgeable
and/or interested in HCC surveillance were more like-
ly to respond. However, we feel these limitations are
outweighed by its notable strengths, including its large,
racially diverse sample size and the fact that it is one of
the first studies to evaluate the combination of sociode-
mographic, clinical, and patient-reported psychosocial
factors affecting HCC surveillance utilization, provid-
ing insight into potential patient-level intervention tar-
gets to increase HCC surveillance rates.
Overall, our study provides important insights into
patient knowledge, attitudes, and barriers regarding
HCC surveillance among patients with cirrhosis.
Despite having overall high levels of HCC-related
knowledge, they have misconceptions about HCC sur-
veillance and report several barriers to implementation.
These misconceptions and perceived barriers might
partly explain the gap between the efficacy of HCC
surveillance and its effectiveness in clinical practice.
Overall, these findings highlight the need for patient
education and systems-level interventions to decrease
barriers for increasing HCC surveillance rates and
optimizing HCC surveillance effectiveness.
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